Orthosteric and Allosteric Modes of Interaction of Novel Selective Agonists of the M1 Muscarinic Acetylcholine Receptor

2010/04/23 by Vimesh A. Avlani, Christopher J. Langmead, Elizabeth Guida +8 · 65 citations
Biochemistry, Genetics and Molecular Biology · Chemistry · Neuroscience · #Agonist #Allosteric regulation #Biochemistry #Chemistry #Competitive antagonist #Muscarinic acetylcholine receptor #Muscarinic acetylcholine receptor M2 #Neuropeptides and Animal Physiology #Neuroscience and Neuropharmacology Research #Receptor #Receptor Mechanisms and Signaling #Stereochemistry #Transmembrane domain

paper · doi:10.1124/mol.110.064345

published in Molecular Pharmacology 78(1), 94-104 (American Society for Pharmacology and Experimental Therapeutics)

openalex publication_date 2010/04/23 · openalex created_date 2016/06/24 · openalex updated_date 2026/07/28

Citations

• Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
• Systematic risk behavior of financially distressed firms

Cited by

• The Best of Both Worlds? Bitopic Orthosteric/Allosteric Ligands of G Protein–Coupled Receptors
• Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. [europepmc]
• Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonism. [europepmc]
• Emerging approaches for treatment of schizophrenia: modulation of cholinergic signaling. [europepmc]
• Allosteric modulation and functional selectivity of G protein-coupled receptors. [europepmc]
• Muscarinic acetylcholine receptors: novel opportunities for drug development. [europepmc]
• Diverse Effects on M 1 Signaling and Adverse Effect Liability within a Series of M 1 Ago-PAMs. [europepmc]
• Disease-Modifying Effects of M 1 Muscarinic Acetylcholine Receptor Activation in an Alzheimer's Disease Mouse Model. [europepmc]
• Heterodimerization of Dibenzodiazepinone-Type Muscarinic Acetylcholine Receptor Ligands Leads to Increased M 2 R Affinity and Selectivity. [europepmc]
• Designing Hybrids Targeting the Cholinergic System by Modulating the Muscarinic and Nicotinic Receptors: A Concept to Treat Alzheimer's Disease. [europepmc]
• Current Advances in Allosteric Modulation of Muscarinic Receptors. [europepmc]
• From structure to clinic: Design of a muscarinic M1 receptor agonist with potential to treatment of Alzheimer's disease. [europepmc]